Absolutely - but that's not an unusual combination for any pre-revenue biotech company. But - the fact that they are getting started on a Phase II set of tests for a trauma for which there is no other treatment,.... well,... that's got potential to go with the risk.
I've sold out a couple years ago - right before that last R/S in 2015, but these guys have stayed on my radar. If I get some spare cash to play with - I just might be looking for a decent re-entry point this Fall.
I was mostly waiting to see what the read-out on the first few Parkinson's patients on the Phase I trial was like before I made a move - but maybe before then.
News 
Market Data 
Discover 
